Endocrine Reviews · 2002 · 471 citations · 25 references
MedicineEndocrinologyPharmacotherapyBone MetabolismClinical EpidemiologyMeta-analysisBone HealthBone Metabolism DisordersBone Metabolism PharmacotherapyClinical TrialsOsteoporosisOsteoporosis PharmacotherapyOsteoporosis EpidemiologyOsteoporosis In WomenPostmenopausal Fracture PreventionPostmenopausal Fracture RiskPostmenopausal Osteoporosis TreatmentSecondary Osteoporosis Treatment
III. Risedronate Ann Cranney, MD, MSc; Peter Tugwell, MD, MSc; Jonathan Adachi, MD; Bruce Weaver, MSc; Nicole Zytaruk, RN; Alexandra Papaioannou, MD; Vivian Robinson, MSc, Beverley Shea, BScN, MSc; George Wells, PhD; Gordon Guyatt, MD, MSc; the Osteoporosis Methodology Group; and the Osteoporosis Research Advisory Group IV. Raloxifene Ann Cranney, MD, MSc; Peter Tugwell, MD, MSc; Nicole Zytaruk, RN; Vivian Robinson, MSc; Bruce Weaver, MSc; Jonathan Adachi, MD; George Wells, PhD; Beverley Shea, BScN, MSc; Gordon Guyatt, MD, MSc; the Osteoporosis Methodology Group; and the Osteoporosis Research Advisory Group
25
John A. Professor Kanis, L. Joseph Melton, Claus Christiansen et al. · Journal of Bone and Mineral Research · 1994 · 3.9K citations